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RESULTS: The average VAS value at baseline was 0.65
(SD = 0.19), 0.83 (SD = 0.14) at the end of the study 
and the average change score from baseline to end of
study for the VAS was 0.17 (SD = 0.20). The differences
between the VAS value and the derived preferences
ranged from -0.07 to 0.02 at baseline. Three of the ﬁve
95% conﬁdence intervals (CIs) for the difference between
derived preferences and VAS values at baseline included
zero. At the end of the study the mean of the VAS was
higher than the means for all of the derived preference
methods. The difference between the averages for the VAS
and the derived preferences ranged from 0.01 to 0.11 and
only one of the 95% CIs for the difference included zero.
The change scores for the VAS preferences were greater
than the derived preferences (Differences from 0.07 to
0.13). None of the 95% CIs for the difference in change
scores between VAS preferences and derived preferences
crosses zero.
CONCLUSIONS: The derivation methods produce valid
and responsive measures of patient preference. However,
the derived preference values differ from each other and
directly elicited preference values. Differences in the 
distributions of the directly elicited and derived prefer-
ences will affect inferences and can lead to differing 
conclusions in a cost-utility analysis.
AR3
MOXIFLOXACIN IV/PO MONOTHERAPY IS
COST-EFFECTIVE TO THE GERMAN AND
FRENCH HEALTHCARE SYSTEMS WHEN
COMPARED TO IV/PO
AMOXICILLIN/CLAVULANATE ±
CLARITHROMYCIN IN THE TREATMENT OF
COMMUNITY-ACQUIRED PNEUMONIA
Drummond M1, Becker D2, Hux M2, Chancellor J3,
Duprat-Lomon I4, Sagnier PP5
1Innovus Research (UK) Ltd. and University of York,
Heslington,York, UK; 2Innovus Research Inc, Burlington, ON,
Canada; 3Innovus Research (UK) Ltd, Amersham,
Buckinghamshire, UK; 4Bayer Pharma, Puteaux, France; 5Bayer
plc, Slough, UK
OBJECTIVE: To conduct a cost-effectiveness analysis,
from the perspectives of the German and French health-
care systems, of sequential IV/PO moxiﬂoxacin (MXF)
monotherapy versus standard comparators in hospital-
ized patients with community-acquired pneumonia (CAP)
requiring parenteral treatment. 
METHODS: Costs and consequences over 21 days 
were evaluated based on clinical cure rates 5–7 days 
post-treatment and resource use reported for the 
intention-to-treat population of the TARGET multina-
tional, prospective, randomized, open-label trial. This
trial compared sequential IV/PO MXF (400mg OD) to
IV/PO amoxicillin/clavulanate (AMC) (1.2g IV/625mg
PO TID) ± clarithromycin (CLA) (500mg BID) for 7–14
days in CAP patients. Since the treatment effect on
resource use (hospital length of stay [LOS]) was similar
across countries, resource data from all 10 countries were
pooled and valued using German and French unit prices
to estimate the CAP-related cost to the German Sickness
Funds and French public healthcare sector.
RESULTS: Compared to AMC ± CLA, treatment with
MXF resulted in 5.3% more patients having clinical cure
5–7 days post-therapy (95% CI -0.1%, 12.3%), a statis-
tically signiﬁcant faster response (return to apyrexia 1 day
sooner), and reduction in LOS by 0.81 days within 
the 21-day period. Treatment with MXF resulted in per
patient savings of €266 (Germany) and €381 (France)
compared to AMC ± CLA, primarily due to a shorter
LOS. Sensitivity analyses found these results to be robust
to several costing scenarios. Using bootstrap analysis of
the trial data, the probability of MXF being cost saving
in both countries was estimated to be 95% or greater,
while the probability of MXF being cost-effective was
commensurately higher for acceptability thresholds up to
€2,000 per additional patient cured. 
CONCLUSION: MXF shows clinical beneﬁts and is 
less costly versus AMC ± CLA in the treatment of CAP.
Treatment with MXF is likely to result in cost savings 
to the German and French public healthcare systems.
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OBJECTIVES: To evaluate the psychometric charac-
teristics of the Acute Bronchitis Symptom Severity 
(ABSS) Scale, a new 7-item bronchitis-speciﬁc instrument
designed to measure outcomes in chronic bronchitis (CB)
patients. 
METHODS: Data were obtained from the screening
phase of an international clinical trial comparing the
effectiveness of moxiﬂoxacin to a standard oral anti-
biotic treatment in treating an acute exacerbation of CB. 
Subjects had a primary diagnosis of CB (having presented
with ≥2 episodes of exacerbation in the preceding year,
FEV1 < 85% of predicted value, and history of smoking),
but were not currently experiencing an acute exacerba-
tion. Patients from 19 countries completed the ABSS 
(14 languages) for 8 consecutive evenings. Psychometric
characteristics evaluated were item performance, internal
consistency reliability (Cronbach’s alpha), day-to-day
reproducibility (intraclass correlation coefﬁcient (ICC)),
construct validity (based on correlation with the St.
George’s Respiratory Questionnaire (SGRQ)), and dis-
criminant validity (based on stratiﬁcation by pulmonary
function (FEV1 % predicted)).
RESULTS: 1935 patients were enrolled. Mean age was
63.4 years (± 9.7) and 68% were male. Mean CB dura-
tion was 11.7 (± 9.6) years, with a mean of 2.9 (± 1.3)
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acute exacerbations in the prior year. The ABSS showed
evidence of good internal consistency reliability (Cron-
bach’s alpha = 0.83), reproducibility (ICC = 0.67), and
construct validity (correlation with total SGRQ: r = 0.54,
p < 0.05). Among the subscales, correlation was highest
with the SGRQ Symptom subscale (r = 0.53, p < 0.05),
as expected. Discriminant validity was generally good
based on score spread across pulmonary function cate-
gories (mean score = 0.99 for mild, 1.22 for moderate,
and 1.38 for severe impairment). Psychometric results
were supported across the language versions.
CONCLUSIONS: The ABSS is a valid, reliable scale for
evaluating the symptoms associated with CB during the
stable phase away from an acute episode.
NEUROLOGICAL/PAIN DISORDERS
NP1
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OBJECTIVE: Back pain is a leading cause of absence and
disability in the workplace. Costs associated with losses
in productivity due to back pain are signiﬁcant and may
be as high as the costs of medical care for this condition.
However, there has been limited study of the indirect costs
of back pain in the United States. The objective of this
study was to determine the indirect costs due to back pain
in the U.S. population. 
METHODS: A retrospective analysis of the 1996 portion
of the Medical Expenditure Panel Survey (MEPS) was
conducted. The MEPS provided data from a nationally
representative sample of 22,601 respondents and data
from respondents’ medical care and health insurance
providers and employers. Data included medical condi-
tions and employment information comprised of hourly
earnings, hours worked, and disability days. Back pain
patients who incurred disability days were identiﬁed
using International Classiﬁcation of Diseases (ICD-9-
CM) codes determined by an expert panel of physicians
and coders as indicative of back pain and variables denot-
ing disability days. Indirect costs were calculated for back
pain patients who missed workdays using the human
capital approach. Sample estimates were weighted and
projected to the population and 95 percent conﬁdence
limits for estimates were calculated using the Taylor
expansion method.
RESULTS: Total indirect costs for back pain patients who
missed workdays were $18,533,583,620. Mean indirect
costs were $4,586 per back pain patient who missed
workdays (95% C.L. = $3,852 to $5,321). Relative to the
entire population, the mean indirect costs per person were
$68.92.
CONCLUSIONS: With losses in productivity greater
than $18.5 billion, indirect costs signiﬁcantly contribute
to the total costs of back pain. The indirect costs of back
pain to labor underscore the need to prevent back injury
thereby promoting employee health and maintaining 
productivity.
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Evidence based clinical practice guidelines (EBCPG) were
developed in response to combined direct and indirect
costs of low back pain (LBP) management approaching
approximately $100 billion annually in the US in the
early 1990s; but implementation of them has been slow.
Utilization of diagnostic imaging studies within the 
ﬁrst week of LBP uniformly exceeds all EBCPG 
recommendations.
OBJECTIVES: This investigation seeks to determine the
costs associated with private and HMO primary care, and
chiropractic utilization of diagnostic imaging studies 
conducted within the ﬁrst week of LBP diagnosis. 
METHODS: Systematic searches of Medline and other
databases were conducted, and identiﬁed studies were
reviewed according to inclusion criteria formulated 
from a base case. Medicare charges (2001) were used 
as surrogates of cost. Costs, utilities, and probabilities for
Markov modeling were based on systematic literature
review, database queries, and health care utilization
billing data. Monte Carlo simulation and sensitivity
analyses were performed with DATA Pro.
RESULTS: Of those patients whose symptoms resolved
within one week of diagnosis of LBP, 83%, 32%, 24%,
and 13% sought chiropractic, private family practice,
HMO primary care, and private internal medicine care,
respectively, received at least one diagnostic imaging
study. The difference in total cost between patients who
had an imaging study during their ﬁrst week of care and
those that did not, according to practice type, is $217.61,
$232.72, $229.59, $258.38 per week, respectively. 
CONCLUSION: All four practice settings’ initial utiliza-
tion exceeded that of the EBCPG’s recommended utiliza-
tion of diagnostic imaging studies within the ﬁrst week of
diagnosis of LBP (estimated 3%–4%); chiropractic use
was the most excessive, adding an estimated total cost 
to the system of $18,061.63 per every 100 patients com-
pared to $3358.94 for private internal medicine utiliza-
tion. EBPCG-based interventions to decrease chiropractic
use of imaging studies as diagnostic tools should be
emphasized and explored.
